Protalix BioTherapeutics, Inc.
PLX
$2.81
-$0.045-1.58%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 53.40M | 45.67M | 38.05M | 59.65M | 65.49M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.40M | 45.67M | 38.05M | 59.65M | 65.49M |
| Cost of Revenue | 24.32M | 29.29M | 25.81M | 22.50M | 22.98M |
| Gross Profit | 29.08M | 16.38M | 12.25M | 37.16M | 42.51M |
| SG&A Expenses | 12.19M | 13.34M | 14.41M | 14.96M | 14.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.48M | 54.57M | 52.84M | 51.59M | 55.03M |
| Operating Income | 3.92M | -8.91M | -14.79M | 8.06M | 10.46M |
| Income Before Tax | 4.15M | -9.59M | -15.15M | 6.77M | 8.57M |
| Income Tax Expenses | 1.22M | 18.00K | -456.00K | -79.00K | 254.00K |
| Earnings from Continuing Operations | 2.93 | -9.61 | -14.69 | 6.85 | 8.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.93M | -9.61M | -14.69M | 6.85M | 8.31M |
| EBIT | 3.92M | -8.91M | -14.79M | 8.06M | 10.46M |
| EBITDA | 5.22M | -7.62M | -13.53M | 9.30M | 11.65M |
| EPS Basic | 0.04 | -0.13 | -0.20 | 0.12 | 0.12 |
| Normalized Basic EPS | 0.04 | -0.08 | -0.13 | 0.07 | 0.08 |
| EPS Diluted | 0.00 | -0.14 | -0.22 | 0.02 | 0.03 |
| Normalized Diluted EPS | 0.01 | -0.09 | -0.13 | 0.04 | 0.05 |
| Average Basic Shares Outstanding | 290.11M | 292.51M | 291.24M | 285.09M | 269.54M |
| Average Diluted Shares Outstanding | 331.89M | 300.18M | 302.74M | 312.64M | 297.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |